Therapy News and Research

RSS

Anti-cancer regimens with multiple modes of action increase treatment effectiveness

Cancer may be the Harry Houdini of diseases—it often finds devious ways to escape treatment. Because cancer disables our cellular quality control mechanisms, rampant mutations that cause tumor cells to grow uncontrollably can also generate resistance to anticancer drugs. Even if 99 percent of the tumor is destroyed, that 1 percent can come roaring back. How do we knock out that 1 percent? By attacking the cancer from multiple angles, using multiple treatments and strategies.

20 Aug 2012

Happtique introduces mRx solution for electronically prescribing medical apps

Happtique, a mobile health application store and total app management solution, today announced the commencement of its pilot program of mRx, Happtique's patent-pending solution that enables physicians and other health practitioners to electronically prescribe medical, health, and fitness apps to their patients.

20 Aug 2012

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, reports treating the first patient in its STOP-HF trial.

20 Aug 2012

Protein toxic to nerve cells in AD also contributes to memory loss

The underlying causes of Alzheimer's disease are not fully understood, but a good deal of evidence points to the accumulation of β-amyloid, a protein that's toxic to nerve cells. β-amyloid is formed by the activity of several enzymes, including one called BACE1. Most Alzheimer's disease patients have elevated levels of BACE1, which in turn leads to more brain-damaging β-amyloid protein.

20 Aug 2012

Abbott's XIENCE Xpedition Everolimus Eluting Coronary Stent System receives CE Mark in Europe

Abbott today announced that the XIENCE Xpedition Everolimus Eluting Coronary Stent System received CE Mark in Europe for the treatment of coronary artery disease.

20 Aug 2012

GORE Hybrid Vascular Graft receives CE Mark approval

W. L. Gore & Associates (Gore) has received CE Mark for the GORE Hybrid Vascular Graft. The graft is designed to expand treatment options for optimal outflow by maximizing the number of access sites available.

20 Aug 2012

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin.

18 Aug 2012

Early treatment vital for infantile hemangiomas

US research shows that infantile hemangiomas, otherwise known as “strawberry” birthmarks, grow faster and earlier than previously believed.

17 Aug 2012

HRT linked to ulcerative colitis in postmenopausal women

Taking postmenopausal hormone replacement therapy increases the risk for ulcerative colitis, but not Crohn’s disease, a study shows.

17 Aug 2012

Study examines whether eribulin offers added benefit to women with breast cancer

Eribulin was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy.

17 Aug 2012

Peptide combinations might offer more effective cancer therapy

Two studies suggest that two peptide agents used either together or individually with a low-dose of a standard chemotherapy drug might offer more effective cancer therapy than current standard single-drug treatments.

17 Aug 2012

U-M, IGC launch new joint venture for personalized medicine

As a key step toward providing patients with treatments based on their own DNA profiles, the University of Michigan and the International Genomics Consortium (IGC) have launched a new joint venture that will help usher in an age of personalized medicine.

17 Aug 2012

Researchers identify molecular and protein signatures that predict HCV virus-induced liver injury

Researchers have discovered molecular and protein signatures that predict rapid onset of liver damage in hepatitis C patients following a liver transplant. The markers appeared soon after transplant and well before clinical evidence of liver damage.

17 Aug 2012

Enzalutamide drug extends survival in people with advanced prostate cancer

Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer.

17 Aug 2012

Tofacitinib shows promise in active ulcerative colitis

Tofacitinib can induce a clinical response in the majority of patients with moderate to severe, active ulcerative colitis, a placebo-controlled trial has shown.

16 Aug 2012

Pregnant women who undergo chemotherapy do not appear to increase their baby’s risk of complications

The babies of breast cancer patients who undergo chemotherapy while pregnant do not appear to be at higher risk of complications, according to an Article published Online First in The Lancet Oncology.

16 Aug 2012

Kessler Foundation to present recent findings in spinal cord injury research at ASCIP conference

Scientists from Kessler Foundation are presenting recent findings in spinal cord injury research during Beyond Boundaries: the 2012 Conference of the Academy of Spinal Cord Injury Professionals (ASCIP).

16 Aug 2012

Researchers discover mechanisms responsible for chemoresistance in ovarian cancer

The presence of multiple ovarian cancer genomes in an individual patient and the absence or downregulation of the gene LRP1B are associated with the development of chemoresistance in women with the high-grade serous cancer subtype of ovarian cancer whose disease recurs after primary treatment. These study results are published in Cancer Research, a journal of the American Association for Cancer Research.

16 Aug 2012

Radiosensitivity molecular signature can lead to better radiation therapy decisions for breast cancer

Researchers at Moffitt Cancer Center, working with colleagues in Sweden, the Netherlands and Puerto Rico, have validated a radiosensitivity molecular signature that can lead to better radiation therapy decisions for treating patients with breast cancer.

16 Aug 2012

Tofacitinib drug shows promise against moderate-to-severe ulcerative colitis

An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine.

16 Aug 2012

Therapy News and Research

Anti-cancer regimens with multiple modes of action increase treatment effectiveness

Happtique introduces mRx solution for electronically prescribing medical apps

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

Protein toxic to nerve cells in AD also contributes to memory loss

Abbott's XIENCE Xpedition Everolimus Eluting Coronary Stent System receives CE Mark in Europe

GORE Hybrid Vascular Graft receives CE Mark approval

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Early treatment vital for infantile hemangiomas

HRT linked to ulcerative colitis in postmenopausal women

Study examines whether eribulin offers added benefit to women with breast cancer

Peptide combinations might offer more effective cancer therapy

U-M, IGC launch new joint venture for personalized medicine

Researchers identify molecular and protein signatures that predict HCV virus-induced liver injury

Enzalutamide drug extends survival in people with advanced prostate cancer

Tofacitinib shows promise in active ulcerative colitis

Pregnant women who undergo chemotherapy do not appear to increase their baby’s risk of complications

Kessler Foundation to present recent findings in spinal cord injury research at ASCIP conference

Researchers discover mechanisms responsible for chemoresistance in ovarian cancer

Radiosensitivity molecular signature can lead to better radiation therapy decisions for breast cancer

Tofacitinib drug shows promise against moderate-to-severe ulcerative colitis

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News